TORONTO, July 08, 2026 (GLOBE NEWSWIRE) — Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing novel therapies to treat degenerative muscle diseases, today announced six-month interim data from TRAILHEAD evaluating its investigational drug candidate SAT-3247 in adults living with Duchenne muscular dystrophy (“Duchenne” or “DMD”).
This excerpt is quoted from the original release. Read the full announcement on GlobeNewsWire.
Brief Summary
Satellos Bioscience has released interim data from the TRAILHEAD study, focusing on the effects of its investigational drug SAT-3247 in adults with Duchenne muscular dystrophy. This data demonstrates substantial progress in muscle health metrics.
- Reduced Muscle Fat Fraction: Suggests improvement in muscle composition.
- Increased Patient Effort: Indicative of better physical functionality.
- Stable Strength Levels: Muscle stability maintained over six months.
- Lower CK Levels: Reduction in creatine kinase points to decreased muscle damage.
- Favorable Safety Profile: Highlights the tolerability of SAT-3247.
Why it matters: These findings could mark a pivotal moment in the treatment landscape for DMD patients, underscoring the therapeutic potential of SAT-3247.
Read the Full Article
This is a summary of the press release. For the complete article and any additional details, please visit the original source.
Attribution: Original press release by GlobeNewsWire on . We provide an AI-generated summary and links for convenience. Always verify details with the original source. Not investment advice. For informational purposes only.